![Marco Loddo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Marco Loddo is the Scientific Director and founder of Oncologica UK Ltd, which was founded in 2014.
Postes actifs de Marco Loddo
Sociétés | Poste | Début |
---|---|---|
Oncologica UK Ltd.
![]() Oncologica UK Ltd. Medical/Nursing ServicesHealth Services Oncologica UK Ltd. is a precision cancer genomics laboratory based in the prestigious Chesterford Research Park, UK. Oncologica provides personalised genetic DNA profiling to identify the most appropriate targeted therapy for increased treatment success. The British company's research activities focus on the development of novel genomic diagnostic and therapeutic approaches directed at specific cancer gene mutations. Throughout the COVID-19 pandemic, Oncologica has utilised its expertise in molecular testing to support the Department of Health and Social Care national testing programme as part of the COVID-19 testing network of laboratories and is now contributing to the international travel testing programme. The private company's genetic test can identify patients most likely to respond to immunotherapy and tap into the potential of genome-based medicine. Oncologica's contract research services laboratory on the Chesterford Research Park is UKAS accredited and ISO15189 certified. The company also offers state-of-the-art molecular tissue analytics for cancer diagnosis, patient stratification, and personalised medicine. The company was founded in 2014 by Marco Loddo and Gareth H. Williams, and the CEO is Patrick D. Downey. | Fondateur | 01/11/2014 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Oncologica UK Ltd.
![]() Oncologica UK Ltd. Medical/Nursing ServicesHealth Services Oncologica UK Ltd. is a precision cancer genomics laboratory based in the prestigious Chesterford Research Park, UK. Oncologica provides personalised genetic DNA profiling to identify the most appropriate targeted therapy for increased treatment success. The British company's research activities focus on the development of novel genomic diagnostic and therapeutic approaches directed at specific cancer gene mutations. Throughout the COVID-19 pandemic, Oncologica has utilised its expertise in molecular testing to support the Department of Health and Social Care national testing programme as part of the COVID-19 testing network of laboratories and is now contributing to the international travel testing programme. The private company's genetic test can identify patients most likely to respond to immunotherapy and tap into the potential of genome-based medicine. Oncologica's contract research services laboratory on the Chesterford Research Park is UKAS accredited and ISO15189 certified. The company also offers state-of-the-art molecular tissue analytics for cancer diagnosis, patient stratification, and personalised medicine. The company was founded in 2014 by Marco Loddo and Gareth H. Williams, and the CEO is Patrick D. Downey. | Health Services |